Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 1.13 (+0.04), AGEN: 3.85 (unch), INO: 9.11 (-0.09), NBS: 3.27 (+0.02), OSIR: 14.87 (+0.13), TEVA: 57.09 (+0.33), ATHX: 1.30 (-0.03)
Cesca Therapeutics names Denis Michael Rhein to board
M2 - Mon Dec 08, 6:01AM CST
Medicine company Cesca Therapeutics (NasdaqCM:KOOL) said on Friday that Denis Michael Rhein has been elected to its board of directors.
KOOL: 1.13 (+0.04)
Cesca Therapeutics Appoints Mr. Denis Michael Rhein to Its Board of Directors
GlobeNewswire - Fri Dec 05, 4:59AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Denis Michael Rhein (54) has been appointed to the Company's Board of Directors.
KOOL: 1.13 (+0.04), DB: 30.95 (+0.04)
Cesca Therapeutics Invited to Present at LD Micro Conference and the World Stem Cell Summit
GlobeNewswire - Wed Nov 26, 5:24AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company announced today that the Company will present at the LD Micro Conference on Tuesday, December 2nd and at the World Stem Cell Summit on Wednesday, December 3rd.
KOOL: 1.13 (+0.04)
Cesca up on IDE filing
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 2:50PM CST
KOOL: 1.13 (+0.04)
Cesca Therapeutics Announces Filing of U.S. Pivotal IDE Application for No-Option Critical Limb Ischemia ("CLI"
GlobeNewswire - Thu Nov 20, 5:34AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company developing proprietary devices and methods for cardiovascular, orthopedic and hematological/oncological procedures, today announced it has submitted an investigational device exemption ("IDE"
KOOL: 1.13 (+0.04)
Cesca Therapeutics' (KOOL) CEO Robin Stracey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 15, 12:39AM CST
KOOL: 1.13 (+0.04)
Cesca Therapeutics misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:16PM CST
KOOL: 1.13 (+0.04)
Cesca Therapeutics Reports First Quarter Fiscal 2015 Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Company Completes Its Pivotal Clinical Trial Protocol for Treating Patients With Critical Limb Ischemia for Submission to the FDA
KOOL: 1.13 (+0.04)
Cesca reports tomorrow
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:29AM CST
KOOL: 1.13 (+0.04)
Cesca Therapeutics to Announce First Quarter Fiscal 2015 Results on November 13, 2014
GlobeNewswire - Wed Nov 12, 5:00AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal first quarter ended September 30, 2014, on Thursday, November 13, 2014.
KOOL: 1.13 (+0.04)
Cesca Therapeutics Announces Change in Executive Leadership
GlobeNewswire - Wed Oct 29, 8:11AM CDT
Cesca to Search for Industry Veteran to Advance its Clinical and Commercialization Strategy
KOOL: 1.13 (+0.04)
Cesca Therapeutics Shareholders Reporting Group File 13D
Marketwired - Mon Oct 27, 10:02AM CDT
A Schedule 13D has been filed with the U.S. Securities and Exchange Commission on behalf of a group of shareholders in Cesca Therapeutics, a company formed by the merger earlier this year of leading cell-therapy device-maker ThermoGenesis Corp. and regenerative medicine clinical therapy company TotipotentRX, engaged in the research, development, and commercialization of point-of-care cell-based therapeutics for use in multiple chronic medical illnesses, including critical limb ischemia and acute myocardial infarction.
KOOL: 1.13 (+0.04)
Cesca Therapeutics to provide blood storage, processing and consumable platform to Upstate Cord Blood BankCesca
M2 - Mon Oct 13, 8:40AM CDT
Medicine company Cesca Therapeutics (NasdaqCM:KOOL) reported on Monday the receipt of an agreement to provide its cell storage, processing and consumables platform to Upstate Medical University's, Upstate Cord Blood Bank located in New York State, USA.
KOOL: 1.13 (+0.04)
Cesca Therapeutics Announces Agreement With New York Upstate Cord Blood Bank
GlobeNewswire - Mon Oct 13, 5:00AM CDT
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has successfully secured a contract to provide its cell storage, processing and consumables platform to Upstate Medical University's, Upstate Cord Blood Bank, one of two public blood cord banks in New York State and one of 27 total public cord blood banks in the United States.
KOOL: 1.13 (+0.04)
Cesca Therapeutics to Present at Stem Cell Meeting on the Mesa
GlobeNewswire - Mon Oct 06, 5:00AM CDT
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company announced today that Kenneth Harris the Company's President will present at the 4 Annual Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
KOOL: 1.13 (+0.04)
Cesca Therapeutics passes TFDA's approval for sale of AXP AutoXpress System in Taiwan
M2 - Mon Sep 29, 6:27AM CDT
Regenerative medicine company Cesca Therapeutics (NasdaqCM:KOOL) reported on Monday that it has received approval from the Taiwan Food and Drug Administration (TFDA) for the sale and distribution of its AXP AutoXpress System and related cell processing bag-set in Taiwan.
KOOL: 1.13 (+0.04)
Cesca Therapeutics Announces Approval of Its AXP(R) AutoXpress(R) System in Taiwan
GlobeNewswire - Mon Sep 29, 5:05AM CDT
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has received approval from the Taiwan Food and Drug Administration ("TFDA"
KOOL: 1.13 (+0.04)
Cesca Therapeutics Reports Fourth Quarter and Full Fiscal 2014 Results
GlobeNewswire - Mon Sep 29, 5:00AM CDT
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the fourth quarter and year-ended fiscal 2014.
KOOL: 1.13 (+0.04)
Cesca Therapeutics Reschedules Fourth Quarter and Full Year Earnings Release
GlobeNewswire - Thu Sep 25, 3:30PM CDT
Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today that it is rescheduling its previously announced earnings conference call for fiscal year end 2014. The Company intends to reschedule the conference call to provide additional time necessary to finalize its accounting for income taxes associated with purchase accounting for the merger with TotipotentRX, which is a non-cash item. The original conference call was scheduled for today, September 25, 2014 at 2:00 PM Pacific (5:00 PM Eastern).
KOOL: 1.13 (+0.04)